The GPRIN1 Knockout HT29 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population in which the GPRIN1 gene has been disrupted to create a loss-of-function model. This product is derived from the HT29 human colorectal adenocarcinoma cell line and is supplied as a mixed population of edited cells, enabling pooled functional analyses without clonal selection. The polyclonal format supports robust representation of genetic heterogeneity, facilitating studies that require population-level responses.
The HT29 cell line is a well-characterized human colorectal adenocarcinoma model with epithelial morphology, originally isolated from a female Caucasian patient. These cells are extensively used in cancer research for investigating intestinal tumor biology, drug responses, and epithelial-mesenchymal transition. Their adherent growth and stable karyotype make them suitable for gene editing and downstream assays.
GPRIN1 (G Protein-Regulated Inducer of Neurite Outgrowth 1) encodes a signaling adaptor that promotes neurite extension and is implicated in cell proliferation and migration. Mechanistically, GPRIN1 binds directly to G protein ?¦? subunits (GNB1, GNG2) and 14-3-3 proteins, linking G protein-coupled receptor (GPCR) activation to MAP kinase and Rho GTPase pathways. Upon GPCR stimulation, liberated G?¦? complexes interact with GPRIN1, leading to activation of ERK1/2 and Rho family GTPases such as Rac1 and Cdc42, which in turn orchestrate cytoskeletal reorganization. This signaling cascade integrates neurotrophic factor cues and GPCR signals to regulate morphological differentiation and cell motility.
In the context of HT29 colorectal cancer cells, GPRIN1 knockout is expected to perturb GPCR-to-MAP kinase and Rho GTPase signal transduction, potentially altering cell proliferation, migration, and adhesion. Because HT29 cells retain epithelial characteristics and respond to GPCR ligands, disruption of GPRIN1 offers a tractable model to dissect how G?¦?-dependent signaling contributes to malignant phenotypes. This knockout population may reveal GPRIN1-dependent effects on wound healing, transwell migration, and growth kinetics, providing insights into its role in colorectal cancer progression.
Researchers can employ this knockout cell pool in a wide range of applications, including functional dissection of GPCR signaling, validation of GPRIN1 as a therapeutic target, and investigation of neuronal differentiation programs in an epithelial cancer background. Typical assays include western blotting and RT-qPCR for confirming gene disruption, immunofluorescence to assess cytoskeletal changes, wound healing and transwell migration assays for motility, MTT assays for proliferation, co-immunoprecipitation to study protein complexes, and cAMP or calcium flux assays to monitor GPCR activity. The polyclonal population is well-suited for pooled screening approaches and RNA-seq transcriptomic profiling. For additional technical details, please contact Ascent Research.
